DotBio
PrivateLast Round
Early Funding
Aug 7, 2023
Total Funding Raised
$8.45M
Company Overview
DotBio operates in Healthcare & Life Sciences and is based in Singapore. Its latest recorded funding round was an Early Funding round in August 2023.
DotBio is a biotechnology company that develops multi-functional and intracellular antibody therapies for immuno-oncology and other therapeutic areas using its proprietary DotBody modular platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DotBio Comparables
Compare DotBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aarvik Therapeutics | 83% | |
| Crescendo Biologics Ltd. | 82% | |
| Chantibody Therapeutics | 79% |
For institutional investors. Book with your work email.
DotBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Aug 7, 2023 | ||||
| Grant | Oct 23, 2020 | ||||
| Corporate Funding | Sep 15, 2020 | ||||
| Seed | Jul 30, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
DotBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Startup SG | Grant |
| NTUitive | Seed |
| National Foundation for Cancer Research | Early Funding |
| Gaorong Capital | Early Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 7, 2023
$5.6M raised led by Gaorong Capital and aim-hiaccelerator.
- Jul 30, 2018
$2.3M raised from ASLAN Pharmaceuticals and NTUitive.
For institutional investors. Book with your work email.
DotBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about DotBio's valuation, stock price, and market status.
Is DotBio a public or private company?
DotBio is a private company.
What is the current stock price of DotBio?
DotBio is a private company, so its shares have no public market price. Caplight tracks DotBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is DotBio worth (valuation)?
Valuation information for DotBio is not publicly available.
Can I buy DotBio stock?
DotBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was DotBio's last funding round?
DotBio's most recent funding round was Early Funding on August 7, 2023.
Who are the main investors in DotBio?
Key investors in DotBio include Gaorong Capital.
Will DotBio IPO soon?
No public IPO plans have been announced for DotBio.
How can I track DotBio secondary market activity?
Caplight tracks bids, offers, and trades in DotBio's shares on secondary markets.